Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one. Viking Therapeutics (NASDAQ:VKTX) is the perfect example. Interest in weight loss medications is skyrocketing just as the biotech is seeing solid success with its GLP-1 drug trials. They are meeting primary and second endpoints allowing it to anticipate launching Phase 2 trials for its oral version of VK2735 later this year.InvestorPlace - Stock Market News, Stock Advice
LONDON, April 08, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced additional results from the APOLLO phase 1 study of zerlasiran (SLN360) in subjects with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L were published in the Journal of the American Medical Association (JAMA), linked her
It's shaping up to be a tough period for Silence Therapeutics plc ( NASDAQ:SLN ), which a week ago released some...
Silence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript March 13, 2024 Silence Therapeutics plc misses on earnings expectations. Reported EPS is $-0.47 EPS, expectations were $-0.25. SLN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]
Silence Therapeutics ( NASDAQ:SLN ) Full Year 2023 Results Key Financial Results Revenue: UK£25.4m (up 45% from FY...
LONDON, March 13, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights.
LONDON, March 13, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.